What Will Happen to Illumina, Inc. Next? The Stock Just Had Huge Bearish Options Activity

 What Will Happen to Illumina, Inc. Next? The Stock Just Had Huge Bearish Options Activity

In today’s session Illumina, Inc. (ILMN) recorded an unusually high (581) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the October, 2016 put, expecting serious ILMN decrease. With 581 contracts traded and 3574 open interest for the Oct, 16 contract, it seems this is a quite bearish bet. The option with symbol: ILMN161021P00155000 closed last at: $0.75 or 15.4% up. About 664,654 shares traded hands. Illumina, Inc. (NASDAQ:ILMN) has declined 9.16% since March 9, 2016 and is downtrending. It has underperformed by 16.57% the S&P500.

Analysts await Illumina, Inc. (NASDAQ:ILMN) to report earnings on October, 18. They expect $0.91 EPS, up 13.75% or $0.11 from last year’s $0.8 per share. ILMN’s profit will be $100.29 million for 38.09 P/E if the $0.91 EPS becomes a reality. After $0.86 actual EPS reported by Illumina, Inc. for the previous quarter, Wall Street now forecasts 5.81% EPS growth.

Illumina, Inc. (NASDAQ:ILMN) Ratings Coverage

Out of 22 analysts covering Illumina Inc (NASDAQ:ILMN), 7 rate it a “Buy”, 1 “Sell”, while 14 “Hold”. This means 32% are positive. $250 is the highest target while $130 is the lowest. The $173.68 average target is 25.27% above today’s ($138.64) stock price. Illumina Inc has been the topic of 45 analyst reports since July 22, 2015 according to StockzIntelligence Inc. Cantor Fitzgerald downgraded it to “Hold” rating and $165 target price in Tuesday, April 19 report. Morgan Stanley maintained Illumina, Inc. (NASDAQ:ILMN) rating on Tuesday, April 19. Morgan Stanley has “Equal-Weight” rating and $140 price target. Canaccord Genuity maintained the stock with “Hold” rating in Tuesday, October 11 report. The firm has “Equal-Weight” rating by Barclays Capital given on Tuesday, April 19. The stock has “Outperform” rating given by Cowen & Co on Tuesday, April 19. Citigroup maintained Illumina, Inc. (NASDAQ:ILMN) on Wednesday, May 4 with “Buy” rating. Bank of America downgraded the shares of ILMN in a report on Tuesday, April 19 to “Neutral” rating. The rating was downgraded by Citigroup to “Neutral” on Tuesday, October 11. The firm earned “Overweight” rating on Wednesday, October 21 by Piper Jaffray. On Thursday, February 4 the stock rating was downgraded by Canaccord Genuity to “Hold”.

According to Zacks Investment Research, “Illumina Inc. is a leading developer of next-generation tools for the large-scale analysis of genetic variation and function. The company’s tools will provide information that could be used to improve drugs and therapies, customize diagnoses and treatment, and cure disease. The company is developing a comprehensive line of products that can address the scale of experimentation and the breadth of functional analysis required to achieve the goals of molecular medicine.”

Insitutional Activity: The institutional sentiment decreased to 1.1 in 2016 Q2. Its down 0.03, from 1.13 in 2016Q1. The ratio is negative, as 66 funds sold all Illumina, Inc. shares owned while 150 reduced positions. 46 funds bought stakes while 191 increased positions. They now own 137.98 million shares or 3.82% less from 143.46 million shares in 2016Q1.
Vanguard Group holds 0.08% or 8.98M shares in its portfolio. Moreover, Fjarde Ap has 0.11% invested in Illumina, Inc. (NASDAQ:ILMN) for 34,190 shares. Moreover, Congress Asset Mgmt Communications Ma has 0.09% invested in Illumina, Inc. (NASDAQ:ILMN) for 27,006 shares. Kemnay Advisory Services has 1.13% invested in the company for 10,350 shares. Eqis Cap last reported 10,061 shares in the company. The California-based Nelson Roberts Investment Advsr Limited Liability Corp has invested 1.78% in Illumina, Inc. (NASDAQ:ILMN). Royal London Asset Mngmt owns 49,568 shares or 0.11% of their US portfolio. Herndon Mngmt Lc holds 14 shares or 0% of its portfolio. Glenmede Tru Na has 3,311 shares for 0% of their US portfolio. Stone Run Limited Liability Company holds 0.54% of its portfolio in Illumina, Inc. (NASDAQ:ILMN) for 5,950 shares. Moreover, Dai Ichi Life has 0.08% invested in Illumina, Inc. (NASDAQ:ILMN) for 18,727 shares. State Of Wisconsin Invest Board accumulated 193,313 shares or 0.11% of the stock. Benjamin F Edwards And Com Inc accumulated 0.01% or 200 shares. Interest Grp Incorporated, a New York-based fund reported 66,267 shares. The Netherlands-based Pggm Invests has invested 0.07% in Illumina, Inc. (NASDAQ:ILMN).

Insider Transactions: Since April 13, 2016, the stock had 0 insider purchases, and 30 selling transactions for $18.12 million net activity. $668,880 worth of Illumina, Inc. (NASDAQ:ILMN) shares were sold by WHITFIELD ROY A. Another trade for 5,000 shares valued at $685,535 was made by BOWMAN A BLAINE on Thursday, May 12. The insider BRADBURY DANIEL sold $110,613. 12,500 shares were sold by HENRY CHRISTIAN O, worth $2.19M on Wednesday, April 13. On Monday, July 18 FLATLEY JAY T sold $1.50 million worth of the stock or 10,000 shares. Another trade for 1,270 shares valued at $219,543 was made by Stapley Marc on Thursday, September 15. EASTHAM KARIN also sold $726,750 worth of Illumina, Inc. (NASDAQ:ILMN) on Wednesday, June 1.

Illumina, Inc. offers sequencing and array solutions for genetic analysis. The company has a market cap of $15.28 billion. The Company’s services and products serve clients in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. It has a 47.66 P/E ratio. The Company’s clients include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

ILMN Company Profile

Illumina, Inc. (Illumina), incorporated on May 16, 2000, offers sequencing and array solutions for genetic analysis. The Company’s services and products serve clients in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s clients include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies. Illumina provides sample-to-answer solutions to its clients in various areas of translational and clinical genomics, such as reproductive and genetic health, and oncology. Illumina provides reproductive-health solutions, including preimplantation genetic screening and diagnosis (PGS and PGD), noninvasive prenatal testing (NIPT), and neonatal and genetic health testing. The Company’s BaseSpace platform, which can be hosted onsite or in the cloud, integrates directly with its sequencing instruments, facilitates data sharing, provides data-storage solutions and streamlines analysis. It has activities in the United States, Europe, Asia-Pacific and other markets.

More notable recent Illumina, Inc. (NASDAQ:ILMN) news were published by: Fool.com which released: “Why Illumina, Inc. Is Plunging Today” on October 11, 2016, also Investorplace.com with their article: “3 Stocks to Watch Tuesday: Illumina, Inc. (ILMN), Seagate Technology PLC (STX …” published on October 11, 2016, Investorplace.com published: “Why Alcoa Inc (AA), Illumina, Inc. (ILMN) and Seagate Technology PLC (STX) Are …” on October 11, 2016. More interesting news about Illumina, Inc. (NASDAQ:ILMN) were released by: Bloomberg.com and their article: “Illumina Dives as Quarterly Revenue Falls Short of Forecast” published on October 10, 2016 as well as Marketwatch.com‘s news article titled: “Illumina cuts Q3 revenue estimates, shares down 23%” with publication date: October 10, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment